The link between tobacco use and cancer is well-established,but emerging research is revealing a complex relationship,particularly when it comes to gastric and esophageal cancers and the efficacy of modern immunotherapy treatments. While tobacco use considerably increases the risk of developing these cancers, recent studies suggest the impact on patients undergoing immunotherapy is nuanced and requires further investigation. This article delves into the latest findings regarding tobacco use, gastric cancer mortality, and the response to immunotherapy, providing a comprehensive overview of this critical area of cancer research.
The Established Link Between Tobacco and Gastrointestinal Cancers
For decades, a strong correlation has been recognized between tobacco use and an increased risk of several cancers, including those affecting the gastrointestinal (GI) tract. Smoking, whether through cigarettes, cigars, pipes, or chewing tobacco, doubles the likelihood of developing esophageal cancer, particularly the two main types: squamous cell carcinoma and adenocarcinoma. 1 This heightened risk stems from the over 7,000 chemicals present in tobacco smoke, with more than 40 identified as carcinogens – substances that promote cancer cell growth. 2 The digestive system is particularly vulnerable to the harmful effects of tobacco, as highlighted by Johns Hopkins Medicine. 3
Immunotherapy and the Smoking Paradox
Immunotherapy (IO) has revolutionized cancer treatment, harnessing the power of the body’s own immune system to fight cancer cells.However, the impact of prior tobacco use on the effectiveness of IO for gastric, gastro-esophageal junction, and esophageal cancers remains a complex question. Research presented at the American Society of Clinical Oncology gastrointestinal Cancers Symposium explored this very issue.5
Researchers at Princess Margaret Cancer Center in Toronto analyzed data from 204 patients receiving immunotherapy, dividing them into two groups: ever-smokers (54%) and never-smokers (46%). The study revealed a surprising trend: ever-smokers demonstrated superior relapse-free survival (RFS) and overall survival (OS) compared to never-smokers. However, this benefit was accompanied by a significantly higher risk of relapse and death when the treatment intent was curative.
- RFS: 17.2 months (smokers) vs. 13.6 months (non-smokers) (HR, 0.80; 95% CI, 0.49-1.32; P = .39)
- OS: 14.1 months (smokers) vs. 12.4 months (non-smokers) (HR, 0.92; 95% CI, 0.56-1.51; P = .75)
- Risk of relapse: HR, 4.07 (95% CI, 1.26-13.1; P = .019)
- Risk of death: HR, 3.38 (95% CI, 0.40-28.41; P = .26)
Interestingly, the outcomes shifted for patients receiving palliative treatment. Among those with metastatic disease, ever-smokers experienced longer RFS and OS compared to never-smokers. Though,patients with recurrent disease saw worse survival outcomes with a history of smoking.
These findings suggest that the relationship between smoking and immunotherapy response isn’t straightforward. The researchers emphasize the need for further investigation, including the analysis of biomarkers like PD-L1 and tumor mutational burden (TMB), to better understand this complex interaction.
Rising Gastric Cancer Mortality and the Role of Tobacco
beyond the impact on immunotherapy, a separate study presented at the same symposium examined trends in gastric cancer (GC) mortality in the united States between 1999 and 2023. 6 Analyzing data from the CDC WONDER Multiple Cause of Death database, researchers found a concerning increase in age-adjusted mortality rates (AAMRs) for GC.
The study population consisted of 17,357 adults, with a predominance of male patients (75.5%) and White ethnicity (79.5%). The overall AAMR increased by 4.60% annually (95% CI, 3.11-6.18), with similar increases observed in both men and women. Though, a closer look revealed disparities. The most meaningful increase in AAMR occurred between 2003-2006 among male patients (23.29%), while women experienced a peak increase between 2003-2008 (14.75%).
Geographically, the Midwest experienced the highest rise in AAMR (0.45), and rural areas showed greater growth compared to urban areas (0.43 vs. 0.30). Notably,non-Hispanic Black/African American patients exhibited the highest AAMR increase,followed by non-Hispanic White and Hispanic patients.
These findings underscore the urgent need for enhanced tobacco cessation programs, early GC screening initiatives, and targeted public health strategies for at-risk populations. The study highlights that while progress has been made in cancer treatment, preventable risk factors like tobacco use continue to drive mortality rates.
Why Does Smoking Impact Cancer treatment Differently?
The seemingly paradoxical results – improved survival in some immunotherapy settings but increased relapse risk – highlight the complex interplay between smoking, the immune system, and cancer. Several factors may contribute to these observations:
- Immune Modulation: Chronic smoking alters the immune system, potentially making it both more and less responsive to immunotherapy depending on the specific cancer type and treatment approach.
- Tumor Microenvironment: Smoking can change the habitat around the tumor, influencing how cancer cells interact with the immune system and respond to treatment.
- Genetic Predisposition: Smokers may have underlying genetic differences that affect their response to both cancer and immunotherapy.
- Treatment Intensity: The type of treatment (curative vs. palliative) and the overall health status of the patient likely play a role in how smoking impacts outcomes.
Looking Ahead: The Future of Research and Prevention
The research presented at the ASCO GI Symposium emphasizes the critical need for continued investigation into the relationship between tobacco use, immunotherapy, and cancer outcomes. Future studies should focus on:
- Biomarker Analysis: Identifying biomarkers that can predict how patients with a history of smoking will respond to immunotherapy.
- Longitudinal Studies: Tracking patients over longer periods to assess the long-term effects of smoking on cancer survival.
- Personalized treatment Strategies: Developing tailored treatment plans based on a patient’s smoking history, genetic profile, and tumor characteristics.
- public Health Initiatives: Strengthening tobacco cessation programs and raising awareness about the risks of smoking, particularly among vulnerable populations.
Ultimately, preventing cancer through tobacco control remains the most effective strategy. Quitting smoking at any age can significantly reduce the risk of developing cancer and improve treatment outcomes. For those already diagnosed with cancer, understanding the complex interplay between tobacco use and immunotherapy is crucial for optimizing treatment strategies and improving patient care.
